glp-1 agonists marketing strategies 2025 From Science to Strategy: Elevating for MaXimum Patient Impact GLP-1 Receptor Agonist Market Size,

The treatment did not sell well due to the non-coverage of health insurance

Conflict of interest The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

35 Clinical data are limited regarding the use of DPP-4 inhibitors to prevent retinopathy

37 Exenatide, approved in 2005 following its 1992 discovery, was followed by longer-acting agents including liraglutide, albiglutide, dulaglutide, lixisenatide, and semaglutide

G., Annett, M

To continue, please confirm that you are a healthcare professional below